{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-098037","form_type":"8-K","ticker":"BCYC","cik":"0001761612","company_name":"BICYCLE THERAPEUTICS PLC","filed_at":"2022-09-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.950973+00:00","generated_at":"2026-06-23T14:24:38.694007+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bicycle Therapeutics reports BT5528 Phase I dose escalation results: ORR 22% in ovarian, 67% in urothelial cancers","bullets":["Among 9 EphA2-positive ovarian patients, ORR 22% (1 CR, 1 PR), DCR 67%; median 4 prior therapies.","In 3 EphA2-positive urothelial patients, ORR and DCR 67% (2 PRs).","Safety differentiated from EphA2 ADCs: no treatment-related hemorrhage, low-grade neuropathy, rash, eye disorders.","RP2D established at 6.5 mg/m2 every other week; expansion cohorts for ovarian, urothelial, and basket cancers ongoing.","Enrollment ongoing in expansion cohorts of up to 56 patients; updates expected next year."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-098037","json":"https://secwatch.observer/filing/0001104659-22-098037.json","markdown":"https://secwatch.observer/filing/0001104659-22-098037.md","text":"https://secwatch.observer/filing/0001104659-22-098037.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922098037/0001104659-22-098037-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761612/000110465922098037/tm2225232d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T14:24:38.694007+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}